Delivery Order SPE2DR25D3005-SPE2DR26FP7SR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,417.68 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-tablet units) on December 8, 2025, with completion scheduled for December 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $13,037.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on October 23, 2025, with completion scheduled for October 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $23,204.03 firm fixed price delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit doses). This is a non-set-aside, competitively awarded contract with performance to be completed by December 9, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a discrete purchase under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $31.8K delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of June 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) valued at $6,223.32 on September 19, 2025, with an ultimate completion date of September 22, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled at the vendor's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $217,620.97 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 22, 2025, with completion scheduled for September 23, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical supply vehicle running through...
- The Defense Logistics Agency awarded a delivery order valued at $15,339.52 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- SPE2DR25D3005Indefinite Delivery Contract
- SPE2DR25D3005-SPE2DR26FP7SRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,409.40 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on December 2, 2025, with completion scheduled for December 3, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is part of AmerisourceBergen's extensive portfolio supporting military and federal healthcare systems, including the Defense Health Agency, U.S. Coast Guard, and other government health programs. RINVOQ ER is a specialty medication used for treating inflammatory conditions, reflecting the company's role in supplying both brand-name and generic pharmaceuticals across multiple therapeutic domains. As a competitively awarded contract with firm fixed pricing, this order demonstrates AmerisourceBergen's established capability to fulfill federal medical supply requirements efficiently. The company's position as a pharmaceutical prime vendor underscores its critical role in maintaining the global medical supply chain for Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 12/1/25 |